KBC Group
CRSP icon

KBC Group’s CRISPR Therapeutics CRSP Stock Holding History

KBC Group’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.56M Buy
116,847
+113,997
+4,000% +$6.01M 0.01% 456
2025
Q4 		$149K Buy
2,850
+626
+28% +$37.5K ﹤0.01% 1044
2025
Q3 		$144K Hold
2,224
– – ﹤0.01% 1053
2025
Q2 		$108K Sell
2,224
-1,526
-41% -$59.1K ﹤0.01% 1148
2025
Q1 		$128K Sell
3,750
-56,764
-94% -$2.41M ﹤0.01% 1344
2024
Q4 		$2.38M Buy
60,514
+57,696
+2,047% +$2.72M 0.01% 665
2024
Q3 		$132K Buy
2,818
+860
+44% +$43.6K ﹤0.01% 1118
2024
Q2 		$106K Buy
1,958
+351
+22% +$20.3K ﹤0.01% 1129
2024
Q1 		$110K Hold
1,607
– – ﹤0.01% 1075
2023
Q4 		$101K Hold
1,607
– – ﹤0.01% 1063
2023
Q3 		$73K Buy
+1,607
New +$83K ﹤0.01% 1157
2021
Q4 		– Sell
-600
Closed -$67K – 1295
2021
Q3 		$67K Sell
600
-600
-50% -$75.4K ﹤0.01% 1211
2021
Q2 		$194K Hold
1,200
– – ﹤0.01% 1176
2021
Q1 		$146K Hold
1,200
– – ﹤0.01% 1215
2020
Q4 		$1.01M Sell
1,200
-1,200
-50% -$142K ﹤0.01% 1145
2020
Q3 		$200K Hold
2,400
– – ﹤0.01% 1118
2020
Q2 		$176K Buy
2,400
+1,200
+100% +$70.2K ﹤0.01% 1167
2020
Q1 		$51K Hold
1,200
– – ﹤0.01% 1195
2019
Q4 		$73K Buy
1,200
+1,035
+627% +$56.5K ﹤0.01% 1385
2019
Q3 		$7K Sell
165
-1,035
-86% -$49.5K ﹤0.01% 1461
2019
Q2 		$57K Hold
1,200
– – ﹤0.01% 1345
2019
Q1 		$43K Hold
1,200
– – ﹤0.01% 1328
2018
Q4 		$34K Hold
1,200
– – ﹤0.01% 1243
2018
Q3 		$53K Hold
1,200
– – ﹤0.01% 1327
2018
Q2 		$71K Sell
1,200
-500
-29% -$28.5K ﹤0.01% 1204
2018
Q1 		$78K Buy
1,700
+1,000
+143% +$41.3K ﹤0.01% 1195
2017
Q4 		$16K Buy
+700
New +$13.3K ﹤0.01% 1242

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

KBC Group's CRSP Position: Q1 2026 in Review

KBC Group increased its CRISPR Therapeutics (CRSP) stake by 4,000% in Q1 2026, buying an estimated $6.01M and bringing the position to 116,847 shares worth $5.56M. The position accounts for 0.01% of the portfolio, ranked #456.

KBC Group first reported a position in CRSP in Q4 2017 and has held it in 27 quarters since. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • KBC Group held 116,847 shares of CRISPR Therapeutics worth $5.56M as of Q1 2026.
  • KBC Group bought 113,997 CRISPR Therapeutics shares in Q1 2026, an estimated $6.01M.
  • CRISPR Therapeutics made up 0.01% of KBC Group's portfolio in Q1 2026, its #456 holding.
  • KBC Group first reported a position in CRISPR Therapeutics in Q4 2017 and has held it in 27 quarters since.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on KBC Group's 13F filing for Q1 2026, filed 7 May 2026.